A Clinical Study to Evaluate the Safety, and Tolerability of BBM-P002 in the Treatment of Parkinson's Disease

NCT07195825 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

PD

Interventions

GENETIC: Injecting BBM-P002 into the bilateral putamen

Sponsor

Shanghai Xinzhi BioMed Co., Ltd.